Status:
COMPLETED
Use of Nucala in Severe Asthma
Lead Sponsor:
Frisius Medisch Centrum
Collaborating Sponsors:
GlaxoSmithKline
Conditions:
Asthma Severe Persistent Uncontrolled
Eligibility:
All Genders
Brief Summary
The Severe Heterogeneous Asthma Research collaboration, Patient-centred (SHARP) is set up to harmonise severe asthma management across Europe and unravel underlying heterogeneity in a patient-centred ...
Detailed Description
The global prevalence of asthma is approximately 358 million people, of which an estimated 30 million patients live in Europe. Severe asthma is defined as asthma requiring treatment according to GINA ...
Eligibility Criteria
Inclusion
- 1\) Initiated on mepolizumab for treatment of asthma.
Exclusion
- 1\) Participation in an interventional clinical trial in which the treatment regimen and/or monitoring is dictated by a protocol in the study observation period.
Key Trial Info
Start Date :
January 1 2021
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
May 1 2022
Estimated Enrollment :
2100 Patients enrolled
Trial Details
Trial ID
NCT05441059
Start Date
January 1 2021
End Date
May 1 2022
Last Update
July 1 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Medical Centre Leeuwarden
Leeuwarden, Provincie Friesland, Netherlands, 8934 AD